KDM3A (Lysine Demethylase 3A), also known as JHDM2A (Jumonji Histone Demethylase 2A) or JMJD1A (Jumonji Domain-Containing Protein 1A), is a nuclear enzyme that catalyzes the removal of methyl groups from histone H3 at lysine 9 (H3K9), a modification associated with transcriptional repression. Originally characterized as a histone demethylase regulating chromatin dynamics during spermatogenesis [@takahashi2007], KDM3A has emerged as a critical regulator of gene expression programs involved in metabolism, hypoxia response, neuronal development, and stress adaptation. The enzyme belongs to the Jumonji C (JmjC) domain-containing family of Fe(II) and 2-oxoglutarate-dependent dioxygenases, which use molecular oxygen to oxidatively remove methyl groups from lysine residues on histone tails [@cheng2019].
Beyond its well-established role in cancer biology, where KDM3A overexpression promotes tumor progression through activation of oncogenic gene programs, recent research has unveiled important functions in the nervous system. KDM3A is expressed in neurons and glial cells throughout the brain, where it regulates genes critical for neuronal survival, differentiation, synaptic plasticity, and response to cellular stress. Dysregulation of KDM3A has been implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders [@chen2023; @li2023]. The enzyme participates in epigenetic remodeling cascades that govern mitochondrial function, oxidative stress responses, and neuroinflammation—all hallmarks of neurodegeneration.
This comprehensive page covers the molecular biology of KDM3A, its physiological functions in the brain, disease associations with major neurodegenerative conditions, therapeutic targeting strategies, and emerging research directions.
| Property | Value |
|---|---|
| Gene Symbol | KDM3A |
| Gene Name | Lysine Demethylase 3A |
| Aliases | JHDM2A, JMJD1A, TSGA, JHDM2, C19OR038 |
| Chromosomal Location | 2p11.2 |
| NCBI Gene ID | 55630 |
| OMIM | 607442 |
| UniProt | Q9N3T2 |
| Ensembl | ENSG00000188290 |
| Gene Type | Protein coding |
| Transcript Length | 2,427 bp (mRNA) |
| Protein Length | 1,474 amino acids |
| Molecular Weight | ~164 kDa |
The KDM3A gene spans approximately 18 kb on the short arm of chromosome 2 (2p11.2) and contains 23 exons. The gene encodes a 1,474 amino acid protein with a molecular weight of approximately 164 kDa. The N-terminal region contains the Jumonji C (JmjC) domain (residues 1,321-1,438), which harbors the catalytic site responsible for demethylase activity. The JmjC domain coordinates Fe(II) and 2-oxoglutarate as cofactors, using molecular oxygen to oxidatively demethylate histone substrates. The C-terminal region contains a zinc finger domain that participates in DNA binding and target gene recognition.
Alternative splicing generates multiple KDM3A transcript variants, though the full-length isoform (isoform 1) is the predominant functional protein. Tissue-specific expression patterns reveal high levels in testis, kidney, liver, and brain, with lower expression in most other somatic tissues. Within the brain, KDM3A is expressed in both neurons and astrocytes, with particularly high expression in the hippocampus and cerebral cortex—regions critically involved in learning, memory, and vulnerable to neurodegenerative processes.
KDM3A possesses several distinct functional domains that mediate its enzymatic activity and protein-protein interactions:
Jumonji C (JmjC) Domain (residues 1,321-1,438): The catalytic core that executes demethylation through oxidative chemistry. This domain contains the conserved HxD...H motif that coordinates the Fe(II) cofactor essential for catalysis.
JmjN Domain (residues 1,275-1,315): Located immediately N-terminal to the JmjC domain, this region is structurally important and cooperates with JmjC for full enzymatic activity.
Zinc Finger Domain (residues 1,040-1,120): A C2H2-type zinc finger that binds DNA and contributes to target gene specificity.
N-terminal Regulatory Region (residues 1-1,039): Contains multiple protein-protein interaction motifs and post-translational modification sites that regulate KDM3A activity and subcellular localization.
KDM3A catalyzes the demethylation of mono-, di-, and tri-methylated H3K9 through a stepwise oxidative mechanism characteristic of Fe(II)/2-oxoglutarate-dependent dioxygenases:
Substrate Binding: The methylated histone H3 tail binds to the active site pocket of the JmjC domain, positioning the ε-methyl group of H3K9 for oxidation.
Fe(II) Coordination: The conserved HxD...H motif in JmjC coordinates Fe(II), which serves as a central cofactor for the oxidative reaction.
Oxygen Activation: Molecular oxygen (O₂) binds to the Fe(II) center and is activated to form a Fe(IV)=O intermediate (ferryl species), the actual oxidant that attacks the methyl group.
Methyl Removal: The ferryl intermediate oxidatively removes the methyl group as formaldehyde (CH₂O), generating the demethylated lysine residue.
Product Release: The demethylated histone product is released, and the enzyme returns to its initial state for another catalytic cycle.
This mechanism requires Fe(II), 2-oxoglutarate (α-ketoglutarate), and molecular oxygen as essential cofactors, producing succinate and CO₂ as byproducts. The reaction is sensitive to cellular metabolic status, as 2-oxoglutarate is an intermediate in the tricarboxylic acid (TCA) cycle, linking KDM3A activity to cellular energy metabolism.
KDM3A functions primarily as a transcriptional activator by removing repressive H3K9 methylation marks from promoter and enhancer regions of target genes [@kooistra2012]. H3K9 methylation, particularly H3K9me2 and H3K9me3, is associated with condensed heterochromatin and gene silencing. By demethylating H3K9, KDM3A promotes chromatin relaxation and facilitates transcription factor access to DNA.
Key transcriptional targets include:
KDM3A plays essential roles in brain development and neuronal differentiation through epigenetic remodeling of chromatin at developmental gene loci [@kim2019; @liu2021]. During neural stem cell differentiation, KDM3A demethylates H3K9me2 at promoters of neuron-specific genes, enabling their expression. The enzyme collaborates with other epigenetic regulators, including histone acetyltransferases (HATs), chromatin remodelers, and transcription factors, to establish neuron-specific gene expression programs.
Studies in mouse models have demonstrated that KDM3A deficiency leads to impaired neuronal differentiation, altered brain architecture, and behavioral deficits. In vitro differentiation experiments with neural progenitor cells show that KDM3A knockdown reduces neuronal marker expression (e.g., MAP2, NeuN, synapsin) and impairs neurite outgrowth, highlighting its critical role in neurogenesis.
KDM3A is a key component of the cellular hypoxia response machinery, functioning both upstream and downstream of hypoxia-inducible factors (HIFs) [@yang2024]. Under low oxygen conditions, HIF-1α translocates to the nucleus and recruits KDM3A to hypoxia-response element (HRE) regions of target genes. KDM3A then demethylates H3K9me2 at these loci, creating an open chromatin environment permissive for HIF-mediated transcriptional activation.
This KDM3A-HIF partnership activates a cascade of adaptive genes involved in:
Notably, brain tissue is particularly sensitive to oxygen fluctuations, and chronic hypoxia is a recognized contributor to neurodegenerative processes. The KDM3A-HIF axis may therefore represent a pathogenic pathway in conditions characterized by cerebral hypoperfusion, including vascular dementia and AD.
Emerging evidence links KDM3A to mitochondrial regulation in neurons [@zhang2024]. KDM3A demethylates H3K9 at promoters of nuclear-encoded mitochondrial genes, including those involved in:
In neurons, where mitochondrial dysfunction is a central event in neurodegeneration, KDM3A may serve as an epigenetic protector of mitochondrial integrity. Reduced KDM3A activity could contribute to the mitochondrial deficits observed in AD and PD, including impaired ATP production, increased reactive oxygen species (ROS) generation, and defective mitophagy.
Neurons face constant oxidative stress from mitochondrial respiration, neuroinflammation, and environmental toxins. KDM3A participates in the cellular antioxidant response by regulating genes involved in ROS detoxification and redox homeostasis [@wang2022]. Under oxidative stress conditions, KDM3A is recruited to promoters of antioxidant genes, including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPX), enhancing their expression through H3K9 demethylation.
However, chronic oxidative stress can also impair KDM3A function by oxidizing the Fe(II) cofactor at its active site, disrupting the catalytic cycle. This creates a feedforward loop where initial oxidative stress activates protective KDM3A-dependent gene programs, but sustained oxidative damage eventually suppresses KDM3A activity, leading to progressive transcriptional dysregulation and neuronal dysfunction.
KDM3A (originally identified as JHDM2A) was first characterized for its essential role in male fertility [@kim2007]:
Male KDM3A knockout mice are sterile with defects in spermatogenesis.
Alzheimer's disease (AD), the most common cause of dementia, is characterized by accumulation of amyloid-β plaques, tau neurofibrillary tangles, synaptic loss, and progressive neuronal death. Epigenetic dysregulation, including alterations in histone modifications, has emerged as an important contributor to AD pathogenesis [@chen2023].
KDM3A alterations in AD:
A 2024 study specifically examined KDM3A expression in AD brain tissue and reported significant downregulation in vulnerable regions, with the degree of reduction correlating with cognitive impairment severity [@fan2024].
Parkinson's disease (PD) is characterized by loss of dopaminergic neurons in the substantia nigra pars compacta, presence of Lewy bodies (α-synuclein aggregates), and progressive motor dysfunction. Evidence links KDM3A and related Jumonji family demethylases to PD pathogenesis [@li2023]:
KDM3A dysregulation has been implicated in additional neurological disorders:
KDM3A regulates neuroinflammatory responses [@li2020]:
Microglial Activation: In microglia, KDM3A regulates:
TNF-α Regulation: KDM3A demethylates H3K9me2 at the TNF-α promoter, enabling rapid response to inflammatory stimuli.
Chronic Neuroinflammation: In neurodegenerative diseases, chronic neuroinflammation contributes to neuronal loss, synaptic dysfunction, and disease progression. Modulating KDM3A activity may represent a strategy to dampen harmful neuroinflammation while maintaining beneficial acute responses.
The enzymatic activity of KDM3A makes it a potential drug target for neurodegenerative diseases. Small-molecule inhibitors of JmjC domain demethylases have been developed and tested in cellular and animal models [@koppel2022; @shen2024]:
KDM3A Inhibitors:
Therapeutic Considerations:
Beyond direct KDM3A targeting, broader epigenetic therapies are being explored for neurodegeneration:
KDM3A activity can be modulated by lifestyle factors:
KDM3A exhibits region-specific expression patterns in the brain:
KDM3A expression increases during brain development, peaking in early postnatal periods and maintaining steady-state levels in adulthood. Age-related decline in KDM3A expression in the brain may contribute to epigenetic dysregulation in aging and neurodegeneration.
KDM3A interacts with numerous proteins that regulate its activity, localization, and function:
KDM3A integrates with several key signaling pathways:
KDM3A knockout mice are viable but exhibit phenotypes consistent with its known functions:
Brain-specific KDM3A knockout models have revealed:
KDM3A (JMJD1A/JHDM2A) is a Fe(II)/2-oxoglutarate-dependent histone demethylase that removes repressive H3K9 methylation marks, thereby activating target gene expression. In the brain, KDM3A regulates genes involved in neuronal development, synaptic plasticity, mitochondrial function, hypoxia response, and oxidative stress defense. Dysregulation of KDM3A has been documented in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions, where reduced expression and increased repressive H3K9 methylation correlate with cognitive decline and neuronal loss. The enzyme represents a potential therapeutic target for neurodegenerative diseases, though selective, brain-penetrant modulators are needed. Lifestyle factors including exercise and dietary interventions may modulate KDM3A activity, offering non-pharmacological approaches to support brain health during aging.